Literature DB >> 7027299

Vision screening requirements under 52 Early and Periodic Screening Diagnosis and Treatment (EPSDT) Programs.

M C Leske, J Rosenthal, M Soroka.   

Abstract

A 1979 survey of vision screening requirements in 52 Early and Periodic Screening Diagnosis and Treatment (EPSDT) programs revealed that 17 percent of the programs had no requirements, and 17 percent required only distance visual acuity testing. An additional 25 percent required distance vision and ocular muscle-fusion tests only, and the remaining programs required various combinations of three or more tests. Fewer than two-thirds of the programs with requirements had referral criteria for the tests. The ages at which initial testing was required also varied among the programs. The differences in requirements were not related to the demographic, socioeconomic, and other variables analyzed in this study. Programs with specific referral criteria, however, had a higher percentage of referrals for vision screening than those without such criteria. Because of the variability in vision screening standards and referral criteria observed among the programs, the authors conclude that national standards are needed.

Mesh:

Year:  1981        PMID: 7027299      PMCID: PMC1424259     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  2 in total

1.  Current concepts in ophthalmology. Strabismus.

Authors:  R D Reinecke
Journal:  N Engl J Med       Date:  1979-05-17       Impact factor: 91.245

2.  Early and Periodic Screening, Diagnosis, and Treatment Program.

Authors:  H Nussenblatt
Journal:  Am J Optom Physiol Opt       Date:  1979-10
  2 in total
  2 in total

1.  Resolution 8224: parental notification of prescription contraceptives for teenagers.

Authors: 
Journal:  Am J Public Health       Date:  1983-03       Impact factor: 9.308

2.  Increasing worker and community awareness of toxic hazards in the workplace.

Authors: 
Journal:  Am J Public Health       Date:  1985-03       Impact factor: 9.308

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.